About: Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19
Creator	Bazzaro, Martina Clemente, Valentino D'arcy, Padraig
topic	covid:71cc57f25842bdc2a787b138a5c44c30e7aaceb5#this
source	Medline; PMC
abstract	Following the outbreak of novel severe acute respiratory syndrome (SARS)-coronavirus (CoV)2, the majority of nations are struggling with countermeasures to fight infection, prevent spread and improve patient survival. Considering that the pandemic is a recent event, no large clinical trials have been possible and since coronavirus specific drug are not yet available, there is no strong consensus on how to treat the coronavirus disease 2019 (COVID-19) associated viral pneumonia. Coronaviruses code for an important multifunctional enzyme named papain-like protease (PLP), that has many roles in pathogenesis. First, PLP is one of the two viral cysteine proteases, along with 3-chymotripsin-like protease, that is responsible for the production of the replicase proteins required for viral replication. Second, its intrinsic deubiquitinating and deISGylating activities serve to antagonize the host’s immune response that would otherwise hinder infection. Both deubiquitinating and deISGylating functions involve the removal of the small regulatory polypeptides, ubiquitin and ISG15, respectively, from target proteins. Ubiquitin modifications can regulate the innate immune response by affecting regulatory proteins, either by altering their stability via the ubiquitin proteasome pathway or by directly regulating their activity. ISG15 is a ubiquitin-like modifier with pleiotropic effects, typically expressed during the host cell immune response. PLP inhibitors have been evaluated during past coronavirus epidemics, and have showed promising results as an antiviral therapy in vitro. In this review, we recapitulate the roles of PLPs in coronavirus infections, report a list of PLP inhibitors and suggest possible therapeutic strategies for COVID-19 treatment, using both clinical and preclinical drugs.
has issue date	2020-05-15(xsd:dateTime)
bibo:doi	10.3390/ijms21103492
bibo:pmid	32429099
has license	cc-by
sha1sum (hex)	71cc57f25842bdc2a787b138a5c44c30e7aaceb5
schema:url	https://doi.org/10.3390/ijms21103492
resource representing a document's title	Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19
has PubMed Central identifier	PMC7278987
has PubMed identifier	32429099
schema:publication	Int J Mol Sci
resource representing a document's body	covid:71cc57f25842bdc2a787b138a5c44c30e7aaceb5#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/71cc57f25842bdc2a787b138a5c44c30e7aaceb5
is schema:about of	named entity 'LARGE' named entity 'RESPONSIBLE' named entity 'INFECTION' named entity 'CORONAVIRUS' named entity 'COVID-19 TREATMENT' named entity 'REMOVAL' named entity 'CYSTEINE PROTEASES' named entity 'NAMED' named entity 'AFFECTING' named entity 'REGULATE' named entity 'DRUG' named entity 'IMMUNE RESPONSE' named entity 'THERAPEUTIC' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'LIST' named entity 'MULTIFUNCTIONAL ENZYME' named entity 'MAJORITY' named entity 'PAST' named entity 'VIRAL' named entity 'PATHOGENESIS' named entity 'CONSIDERING' named entity 'CORONAVIRUSES' named entity 'HOW' named entity 'PREVENT' named entity 'SPECIFIC' named entity 'INNATE IMMUNE RESPONSE' named entity 'REGULATORY PROTEINS' named entity 'SARS' named entity 'NF-kB' named entity 'SARS-CoV' named entity 'Coronaviruses' named entity 'antiretrovirals' named entity 'MG132' named entity 'COVID-19' named entity 'Broussonetia' named entity 'protease' named entity 'WHO' named entity 'lung' named entity 'enzymatic activities' named entity 'cystatin' named entity 'SARS-CoV' named entity 'MG132' named entity 'SARS-CoV' named entity 'disulfiram' named entity 'COVID-19' named entity 'thiopurine' named entity 'monoclonal antibodies' named entity 'SARS' named entity 'histological' named entity 'ISGs' named entity 'lung' named entity 'downregulation' named entity 'UPS' named entity 'coronaviruses' named entity 'host cell' named entity 'NF-kB' named entity 'PROTACs' named entity 'immunomodulatory' named entity 'ERK1/2' named entity 'retinoid' named entity 'ISG15' named entity 'sequence similarity' named entity 'viruses' named entity 'SARS' named entity 'TLR' named entity 'ubiquitin' named entity 'lung' named entity 'RIG-I' named entity 'intensive care unit' named entity 'innate immune response' named entity 'type I IFNs' named entity 'IFN' named entity 'antiviral' named entity 'ISGs' named entity 'open reading frames' named entity 'SARS' named entity 'pre-clinical development'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software